European Commission (Competition Directorate-General), 1999-08-09: The European Commission's clearance of the Hoechst/Rhone-Poulenc merger that created Aventis, granted on condition that the parties sell Hoechst Roussel Veterinar GmbH, Hoechst's entire animal-health division.
Concerning the sector of animal health, the parties have offered an irrevocable commitment to sell Hoechst Roussel Veterinär GmbH (HRVet), the animal health division of Hoechst, within a time frame agreed by the Commission. Therefore, any overlap as regards the animal health business will be eliminated.
p.29, recital 125
European Commission (Competition Directorate-General), 1999-08-09: The European Commission's clearance of the Hoechst/Rhone-Poulenc merger that created Aventis, granted on condition that the parties sell Hoechst Roussel Veterinar GmbH, Hoechst's entire animal-health division. EU merger decision (public administrative decision, foreign government). Country: EU/Germany/France. Recital 107 records that 'Hoechst is active in the animal health sector through its 100% subsidiary Hoechst [Roussel Vet]'; recital 118 records that Rhone-Poulenc transfers its animal health activities to Aventis. The PDF's embedded fonts garble some characters in the text layer (e.g. accents, annex references); the quoted passage is clean in the extracted text. Companion documents: Akzo Nobel releases FBB-16 and FBB-17. Context: the divestiture put the fenbendazole business (Panacur/Safe-Guard) on the market in 1999, where Intervet bought it. Study type: regulatory record.
